FDA approves quicker-to-administer drug for blood cancers
Share
Tweet
June 23, 2017
U.S. regulators have approved a more convenient version of a blockbuster drug for treating three common blood cancers.
The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take several hours.
On Thursday, the Food and Drug Administration approved the Swiss drugmaker's new version, Rituxan Hycela (RIH'-tux-en HEYE'-cell-uh). It's injected in about six minutes, shortening clinic visits.
It's given every three weeks for six months to treat diffuse large B-cell lymphoma, for a total cost of about $48,600 without insuran...
For access to this article please
sign in or
subscribe.
Reader Comments(0)